Coronavirus daily news update, April 6: What to know today about COVID-19 in the Seattle area, Washington state and the nation – Seattle Times

Washington state appears to be flattening its curve the impact on the hospital system at any one time according to the latest analysis from theUniversity of Washingtons Institute for Health Metrics and Evaluation(IHME). The IHME models suggest the state hit peak resource use on April 2 and project daily COVID-19 deaths will peak today, April 6, before dropping to 18 deaths per day during April 7-9 and declining slowly from there.

The model also revises its estimates of deaths in Washington sharply downward, to 632. Earlier model results had suggested about 1,400 people in the state were likely to die from the disease. IHME has been adjusting its model daily, and the latest results are based on a massive infusion of new data, institute director Christopher Murray said in a statement.

The estimated death toll nationwide remains at around 82,000, similar to earlier estimates. But the upper end of the uncertainly range has been lowered to about 136,400, from previous estimates of nearly 200,000.

Washington will return more than 400 of the 500 ventilators it recently received from the federal government, so they can go to New York and other states harder hit by the coronavirus crisis, Gov. Jay Inslee said Sunday.Vice President Mike Pence commended Inslee for returning the ventilators and said Washington and Oregon are two states leading by example in taking steps to slow the spread of the coronavirus that causes COVID-19.

The state Department of Health mirroring the Centers for Disease Control and Prevention recommends residents wear cloth face masks anytime they are in public and cant guarantee theyll be able to stay 6 feet away from another person.

The state health department on Sunday confirmed an additional 393 cases and 28 deaths from COVID-19 as of 11:59 p.m. Saturday, bringing the states totals to 7,984 cases and 338 fatalities.

Throughout today, on this page, well be posting updates from Seattle Times journalists and others on the outbreak and its effects on the Seattle area, the Pacific Northwest and the world. Updates from Sunday can be found here, and all our coronavirus coverage can be found here.

The following graphic includes the most recent numbers from the Washington State Department of Health, released Sunday.

President Trump and members of the Coronavirus Task Force have scheduled a press briefing for this afternoon.

Leticia Frutos never imagined shed spend weeks avoiding her month-old granddaughter because of her manufacturing job in Bothell.

The Mill Creek resident and material assistant for Ventec Life Systems is one of more than 1,000 workers nationwide on the front lines of Ventecs Project V venture with General Motors to make thousands of ventilators for the nations coronavirus fight.

Ventec, GM and the companies supplyingparts for them say worker safety is a prime concern. Its also a challenge, given the ramp-up inproduction means more workerson the production line, often for more hours per week, and at a hurried pacethat could lead to mistakes safeguarding against COVID-19, the illness caused by the novel coronavirus.

Read the full story here.

Geoff Baker

Thomas Lopez, who ran a fleet of Tacos El Tajin food trucks around Seattle, has died from COVID-19, the disease caused by the novel coronavirus, his family announced Monday afternoon.

After suffering flu-like symptoms, Lopez, 44, was hospitalized last week and put on a ventilator, but his condition got worse and he died on Thursday, his son Isaac Lopez said.

Lopez made national headlines in February 2017 for hawking tacos out of his food truck on Interstate 5 after a semitruck rolled over and brought traffic to a standstill. After realizing he would not make it to South Lake Union for the Amazon lunch rush and seeing how drivers around him were losing their patience, Lopez got out and started selling steak and chicken tacos to commuters as if he were parked in a food-truck pod.

Lopez, a Pacific resident, is survived by his wife Antonia Zamorano and their five children.

Read the full story here.

Tan Vinh

BELLINGHAM Escalating a global spat over workplace safety and the rights ofhealth-care workers during the coronavirus crisis, a top official of PeaceHealth has now confirmed the company ousted emergency physician Ming Lin for allegedly inciting public fear by criticizing the hospitals emergency precautions.

In a lengthy interview on a YouTube video blog popular with medical professionals, Richard DeCarlo, chief operating officer of PeaceHealth, which operates Bellinghams St. Joseph Medical Center, likened Lins public warnings about workplace coronavirus concerns to yelling fire in a crowded theater. He said the hospital had no choice but to remove Lin from his post of 17 years.

Lin said Monday that he had seen the video and urged members of the public to view his Facebook postsand draw their own conclusions. Lin on March 16 accused PeaceHealth management of mishandling early COVID-19 testing; failing to conduct proper triage of patients and staff entering the hospital; and lagging in procedures for protective equipment and other emergency measures.

Read the full story here.

Ron Judd

Boeing said Monday it will suspend its 787 production work in South Carolina until further notice, halting temporarily its last aircraft manufacturing center that was still operating.

The company closed its Seattle-area production facilities March 25, and announced Sunday it would keep them closed indefinitely as the coronavirus ravages airlines finances and the COVID-19 disease forces many factories to close.

Boeing said its suspension in North Charleston, S.C., affects its Airport Campus, Emergent Operations, Interiors Responsibility Center South Carolina and Propulsion South Carolina. Collectively these employ several thousand people in final assembly of the 787 and manufacturing some sections of the plane.

Read the full story here.

Seattle Times business staff

Employees at Valley Medical Center had a brush with COVID-19 even before the outbreak became publicly known in Western Washington after a man twice visited the Renton hospital in late February.

He came into the Emergency Department, got discharged, a few days later came in very sick and was admitted to the critical care unit, said Jamie Park, the hospitals chief medical officer.

In a March 1 conference call, hospital administrators told some clinicians as many as 350 staffers could have been exposed during the mans visits, according to two physicians who listened to the call.

Interviews with more than a dozen front-line Valley employees, including multiple physicians, and copies of emails and internal documents, underscore the concerns of many employees who said that COVID-19s sudden arrival left staff and administrators scrambling. Directives changed regularly and sometimes confusion reigned, fueling employees fears for their safety.

And since the outbreak began, a rift in understanding, amplified by stress, risk and fear, has grown between some Valley employees and management over access to personal protective equipment (PPE), testing availability and criteria and infection-control measures.

Read the full story here.

Evan Bush

Sound Transit will reduce Sounder South service by one round trip starting Wednesday because of reduced staffing availability,the agency said Monday.

A southbound train that departs from Seattle at 7:55 a.m. and a northbound train that departs from Lakewood at 10:16 a.m. will be removed from the schedule.

The reductions follow previous cuts to Sounder service because of concerns around the novel coronavirus pandemic.

Sounder ridership has declined by 92%, the agency said.

Sound Transit and King County Metro last monthbegan reducing service, eliminated fares and asked riders to board through rear doorson buses to reduce contact between drivers and riders.

Michelle Baruchman

The next time more than a million kids in Washington state attend classeswith their peers, it will be a new school year.

Washington schoolswill remain closed through the end of the academic year, Gov. Jay Inslee announced at a Monday news conference.Distance learning is expected to continue, and schools are expected to resume on a normal schedule this fall.

The announcement comes 20 days into a state-mandated closure of all public and private schools in an attempt to slow the spread of coronavirus. The closures werefirst supposed tolast until at least April 24, about six weeks, but state schools chief Chris Reykdal has repeatedly stressed the shutdown could last longer.

We simply cannot take the chance of reopening on site instruction in this calendar school year, Inslee said. We cannot risk losing the gains we have made after the peak of this pandemic presumably will have passed.

Read the full story here.

The Seattle Times

A Kitsap County resident has died of COVID-19, the first person from the county todie from the disease caused by the novel coronavirus, the Kitsap Public Health District said.

The person, who had tested positive for the virus, was an "older adult" with underlying health conditions, the Health District said.

"We were saddened to learn of the death of this community member and our hearts go out to their family and loved ones during this difficult time, Dr. Susan Turner,the district's health officer said. As a community, we must do everything we can to slow the spread of this illness and protect our neighbors who are most at risk. Please continue to stay home, wash your hands, and clean your living spaces. These simple steps can save lives.

As of Monday, 111 Kitsap County residents had tested positive for the virus, out of more than 1,900 tested, the Health District said.

David Gutman

New York City officials are starting to lay chilling contingency plans if deaths from the coronavirus outbreak begin to overwhelm the capacity of morgues: temporarily burying the dead in one of the citys public parks.

Mark Levine, chairman of the City Council health committee, said Monday that the office of the chief medical examiner was looking into creating temporary mass graves in a public park as it confronts the possibility that deaths from the coronavirus outbreak may soon exceed the capacity of city and hospital morgues.

Levine declined to say which park was under consideration, noting only that it would likely have to be a large one out of the way of the public.

Mayor Bill de Blasio said Monday that no such plan had been put in place yet, although he acknowledged it was under consideration.

If we need to do temporary burials to be able to tide us over to pass the crisis, and then work with each family on their appropriate arrangements, we have the ability to do that, he said, adding, We may well be dealing with temporary burials so we can deal with each family later.

Read the full story here.

The New York Times

Major supermarket chains are beginning to report their first coronavirus-related employee deaths, leading to store closures and increasing anxiety among grocery workers as the pandemic intensifies across the country.

A Trader Joes worker in Scarsdale, New York, a greeter at a Giant store in Largo, Maryland, and two Walmart employees from the same Chicago-area store have died of COVID-19 in recent days, the companies confirmed Monday.

Though more than 40 states have ordered nonessential businesses to close and told residents to stay home to stem the spread of the virus, supermarkets are among the retailers that remain open.

Read the full story here.

The Washington Post

British Prime Minister Boris Johnson was moved to the intensive care unit of a London hospital after his coronavirus symptoms worsened Monday, just a day after he was admitted for what were said to be routine tests

Johnson was admitted to St. Thomas Hospital late Sunday, 10 days after he was diagnosed with COVID-19.

Over the course of this afternoon, the condition of the Prime Minister has worsened and, on the advice of his medical team, he has been moved to the Intensive Care Unit at the hospital, his office said in a statement.

Downing St. said Johnson was conscious and does not require ventilation at the moment, but was in the intensive care unit in case he needed it later.

Read the full story here.

The Associated Press

Seattle's Woodland Park Zoo has canceled ZooTunes, its popular summer concert series, as well as summer day camps and other special events.

The zoo has been closed since early March because of the coronavirus pandemic.

The zoo, in a social media post, said it decided to cancel the summer events to "put community safety first and focus our resources and staff on our animals."

It said it has lost millions of dollars in revenue since it closed, nearly a month ago.

David Gutman

Tim Eyman, the anti-tax advocate and Republican candidate for governor, is urging his supporters to come to Seattle City Hall Monday afternoon to protest a new tax proposal at the weekly City Council meeting.

But there will be no City Council meeting at Seattle City Hall.

The City Council has moved to all-remote meetings, by teleconference, to slow the spread of the novel coronavirus.

Eyman, in a letter to supporters Monday morning, seemed unaware.

"Would we have beaten the British in the Revolutionary War if George Washington and his patriots had stayed home?" Eyman wrote. "At 1 p.m., at the east entrance to City Hall (dress warm), we will stay 6 feet apart and walk in together. We'll have signs for you. We'll have gloves and hand-sanitizer for you."

They will be waving signs to no one. While City Hall, and the Council chambers, will be unlocked, there will be no one there, except a staff member to operate a conference call line. City Council members will be participating from their homes.

Eyman is aware of his mistake. Seattle City Clerk Monica Martinez Simmons said she sent him a note letting him know Council chambers are closed (even if the room is not locked).

He did the same thing at an Edmonds City Council meeting two weeks ago, My Edmonds News reported, showing up to a meeting that was being held remotely.

Democratic State Rep. Gerry Pollet, an instructor at the University of Washington's School of Public Health, said it was "unconscionable" to encourage a gathering, like Eyman is doing.

"Eyman is demonstrating absolute ignorance of our states measures to prevent the spread of COVID-19," Pollet said. "Its inexcusable for anyone seeking to be in a position of leadership to be unaware of those measures."

Council members Kshama Sawant and Tammy Morales have been proposing a tax on big businesses, like Amazon. To "attend" the council meeting, tune in to the Seattle Channel or call 206-684-8566.

Council President M. Lorena Gonzalez said Monday she hopes to develop a tool to accept public comments during remote council meetings, but that won't be operational for at least a couple weeks.

David Gutman

Deja Vu Showgirls, an adult entertainment club in downtown Seattle, appears to be closed or clothed until April 30, according to a banner announcement outside the venue.

The club, across the street from Pike Place Market, is generally open 2 p.m. to 2:30 a.m. daily.

The windows have been boarded up with plywood as many other shops downtown have emptied in response to Gov. Jay Inslees stay-at-home order.

Jon Talton and Michelle Baruchman

Alaska Air Group said Monday it is cutting capacity for April May further than announced just two weeks ago, as it continues to experience demand that is 80% or more below normal levels.

In a regulatory filing, the company said, Today we are updating our capacity reduction plans to reflect 80% cuts in both April and May.

The parent of Alaska Airlines and Horizon Air added that for June and beyond, given current trends and circumstances, it is our expectation that sizable cuts will be necessary for the coming months.

Read the full story.

Seattle Times business staff

Washington State Superintendent Chris Reykdal says school buildings may stay closed through the end of the school year. Since schoolsclosed in mid-March, Reykdal and Gov. Jay Inslee have said buildings would remain closed until at least April 24.

Read more from the original source:
Coronavirus daily news update, April 6: What to know today about COVID-19 in the Seattle area, Washington state and the nation - Seattle Times

BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority – Yahoo Finance

NEW YORK and PETACH TIKVAH, Israel, April 03, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority (IIA). The grant enables Brainstorm to continue development of advanced cellular manufacturing capabilities, furthers development of MSC-derived exosomes as a novel therapeutic platform, and will ultimately enable Brainstorm to expand the therapeutic pipeline in neurodegenerative disorders.

BrainStorm's CEO Chaim Lebovits, commented, "The Israel Innovation Authority's support of our programs provides further validation for the potential of our treatments to help patients suffering from neurodegenerative disorders. The continued financial support for our research and development will further our ability to execute our strategic objectives, as we finalize our Phase 3 pivotal trial with NurOwn in ALS patients and advance our cellular technology pipeline."

The IIA has supported BrainStorm Cell Therapeutics Ltd. since 2007, providing grants totaling approximately 11.4 million USD in support of the development of NurOwn and other projects. BrainStorm will be required to pay mid-single digit royalties to the IIA based on sales of the products, up to a total of the cumulative amount of IIA grants received plus accumulated interest.

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

Story continues

AboutBrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in theU.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. BrainStorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor Statement Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTSInvestor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: + 1.862.397.1860pshah@brainstorm-cell.comMedia:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Go here to read the rest:
BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority - Yahoo Finance

Post-Remission Therapy For AML: Allogeneic Stem-Cell Transplant – SurvivorNet

When treating Acute Myeloid Leukemia, its important to recognize the distinction between remission and cure. When their Acute Myeloid Leukemia is in remission and everything looks good, a lot of patients say, Thanks. Im done, right? saysDr. Richard Stone, director of the Adult Acute Leukemia Program at Dana-Farber Cancer Institute in Boston.

Instead, when a patient enters remission, it signals that theyre ready for the final phase of treatment. Post-treatment therapy offers the chance of a cure. It also reduces the risk of a recurrence, which can be caused by residual leukemia cells that may have remained in the blood after treatment.

Oh no. Sorry, Dr. Ston tells patients who assume remission means their treatment is over. We need to give you some more therapy to kill off those residual, undetectable leukemia cells, so we can go from remission to cure, he explains.

And thats really what were talking about in AML therapy today. We want to get you into remission and we have a great chance of doing that in most patients. And we want to cure you with post-remission therapy.

And autologous stem cell transplant involves taking the patients own stem cells, giving them high doses of chemotherapy, and then giving those cells back. We dont do that very much, says Dr. Stone.

The other big choice isallogeneic stem cell transplant, often called bone marrow transplant.And thats where we give you, the patient, chemotherapy to put your immune system to sleep, says Dr. Stone, adding that sometimes radiation is included in the pre-transplant treatment plan for the same purpose.And then we give you cells from another individual.

We give you those (donor) cells to replenish your bone-marrow compartment, where we expect those donated cells tokill off the residual undetected leukemic cells. The result is called Graft vs. Leukemia effect, which means the donor cells have killed off any residual leukemia cells. Thats why stem-cell transplantation is a very effectiveanti-leukemic therapy, Dr. Stone explains.

Why dont we do it in everybody? he asks. Because its pretty dangerous and we dont do unless we really think thats the only way we have to cure you.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Richard Stone is Director of the Adult Acute Leukemia Program at DFCI. Read More

When treating Acute Myeloid Leukemia, its important to recognize the distinction between remission and cure. When their Acute Myeloid Leukemia is in remission and everything looks good, a lot of patients say, Thanks. Im done, right? saysDr. Richard Stone, director of the Adult Acute Leukemia Program at Dana-Farber Cancer Institute in Boston.

Instead, when a patient enters remission, it signals that theyre ready for the final phase of treatment. Post-treatment therapy offers the chance of a cure. It also reduces the risk of a recurrence, which can be caused by residual leukemia cells that may have remained in the blood after treatment.

And thats really what were talking about in AML therapy today. We want to get you into remission and we have a great chance of doing that in most patients. And we want to cure you with post-remission therapy.

And autologous stem cell transplant involves taking the patients own stem cells, giving them high doses of chemotherapy, and then giving those cells back. We dont do that very much, says Dr. Stone.

The other big choice isallogeneic stem cell transplant, often called bone marrow transplant.And thats where we give you, the patient, chemotherapy to put your immune system to sleep, says Dr. Stone, adding that sometimes radiation is included in the pre-transplant treatment plan for the same purpose.And then we give you cells from another individual.

We give you those (donor) cells to replenish your bone-marrow compartment, where we expect those donated cells tokill off the residual undetected leukemic cells. The result is called Graft vs. Leukemia effect, which means the donor cells have killed off any residual leukemia cells. Thats why stem-cell transplantation is a very effectiveanti-leukemic therapy, Dr. Stone explains.

Why dont we do it in everybody? he asks. Because its pretty dangerous and we dont do unless we really think thats the only way we have to cure you.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Richard Stone is Director of the Adult Acute Leukemia Program at DFCI. Read More

See original here:
Post-Remission Therapy For AML: Allogeneic Stem-Cell Transplant - SurvivorNet

Intermittent fasting might boost the creation of new neurons in a key brain structure – PsyPost

The connection between what and when we eat, and the structure and functionality of the brain, is one of the most complex relationships in modern medicine. But understanding this relationship will lead to fewer diseases, healthier minds, and longer lives. One regimen in particular, Intermittent Fasting (IF), has been shown to bolster the creation of new neurons (a process known as neurogenesis) in the hippocampus, a part of the brain involved in short and long term memory (and also one of the first casualties of Alzheimers disease).

Intermittent Fasting is a type of diet in which one regularly forgoes food for a certain period of time, usually somewhere between 14 and 18 hours. While its been known that IF increases the rate of hippocampal neurogenesis, the precise nature of the relationship is still poorly understood. To remedy this, researchers from the Universities of Singapore and Sungkyunkwan in Korea took a closer look at how IF affected change in the hippocampi of mice over a three month period in new research published in Brain and Behavior.

The mice were randomly assigned to four dietary groups: a control with no restrictions, and 12-hour, 16-hour and 24-hour fasted diets. The 12- and 16-hour groups fasted from either 3PM or 7PM to 7AM the next day, while the 24-hour group fasted every other day. Despite the varied schedules, all the mice ended up eating roughly the same number of calories.

As expected, all three dietary groups showed increased levels of neurogenesis in the hippocampus, with the most significant change in 16-hour mice. To better understand what was going on, the authors used a procedure called an immunoblot analysis, which can accurately detect certain proteins in a given tissue sample.

The analysis revealed an increased activation of the Notch signaling pathway, a type of cell-to-cell communication thats important to cell differentiation, the process by which immature cells, like stem cells, take on a permanent form and function. In humans, Notch signaling is related to hippocampal neuroplasticity, the brains ability to create new connections, allowing us to learn and form new memories.

We still have a long way to go before fully understanding how our diets affect the structure and function of our brains. Studies like this one can help us make better-informed decisions for leading healthier and longer lives, while retaining our memories and maintaining cognitive faculties.

The study, Intermittent fasting increases adult hippocampal neurogenesis, was authored by SangHa Baik, Vismitha Rajeev, David YangWei Fann, DongGyu Jo, and Thiruma V. Arumugam.

Read the original here:
Intermittent fasting might boost the creation of new neurons in a key brain structure - PsyPost

Twins Daily: How would a shortened season impact MLB injuries? – Bring Me The News

Andy Witchger / Bring Me The News

When major league baseball will resume is anybodys guess. But assuming baseball does have some semblance of a season during the 2020 calendar year, how will it impact the health of MLBers, however stunted it may be?

When major league baseball will resume is anybodys guess. But assuming baseball does have some semblance of a season during the 2020 calendar year, how will it impact the health of MLBers, however stunted it may be?

In many ways this is an impossible question to answer with any sort of confidence at this time. For instance, we dont know when the season will begin, when it will end, the amount of doubleheaders it will contain, if roster sizes will extend and for how long, nor to what extent will there be an extended Spring Training, among other factors that may be in play during the upcoming season.

It seems intuitive that injury rates may increase during the upcoming season as athletes and teams will assuredly have less time to prepare physically compared to a typical season with a typical Spring Training; during the strike-shortened 1995 season, MLB had a three-week Spring Training prior to beginning the regular season on April 25th, which may serve as precedent for how MLB will handle the upcoming season.

While athletes around the league are doing their best to remain in game-shape, each week without access to live pitching and batting practice at game speed decreases the likelihood that the athletes will remain ready for action.

There is some debate, however, regarding the role that Spring Training plays in athlete injury prevention. Spring Training likely decreases injury rates as many musculoskeletal injuries - among athletes as well as the lay population - occur after a sharp increase in activity which was preceded by relatively less activity, however, to what extent is unknown and likely impossible to study with a high-degree of accuracy.

Injury rates are usually highest among MLB athletes during the early portions of the season. A study conducted in 2011 found that injury rates during the 2002-2008 seasons were highest during April (5.73 injuries per 1,000 athlete exposures) and steadily decreased throughout the rest of the season, bottoming out at an injury rate of 0.54 during September.

Later studies published in 2019 and 2020 found that lower body and upper body injuries, respectively, suffered during the 2010-2016 seasons had the highest occurrence during the month of April (24% of all upper extremity and 21% of all lower extremity injuries suffered over the six year timeframe); these same studies found, perhaps unsurprisingly, that pitchers were more likely to suffer upper extremity injuries, whereas position players were more likely to suffer lower extremity injuries.

This is a guess, but it would not surprise me to see an increase in the rate of lower extremity soft tissue injuries - i.e. muscle strains - during the first month or two of the 2020 regular season compared to other seasons, particularly among position players, due in large part to the likely shortened Spring Training interval.

However, as long as pitchers are stretched out and brought along at an appropriate pace - such as capping pitch counts and limiting innings - I could see upper extremity injuries maintaining similar rates compared to previous seasons.

In all reality, it will be impossible to know how the shortened season impacts MLB athlete injury occurrence until after the 2020 season has been completed, and even then how late the season extends into the calendar year as well as the percentage of games that are played as doubleheaders will likely influence the overall rates of injury. We may never truly know the answer as to how MLB athlete health was impacted during the 2020 season.

Blaine Hardy Undergoes Tommy John SurgeryPhil Miller of the Star Tribune dropped a surprising nugget Saturday afternoon when he reported that reliever Blaine Hardy underwent Tommy John surgery recently to address a torn UCL and damaged flexor-pronator mass in his left elbow. Hardy was signed to a minor league contract by the Twins during the offseason.

Hardy dealt with left elbow pain during his 2019 campaign with the Detroit Tigers - spending time on the injured list twice, including a 60-day stint - and received a PRP injection in August to address his pain under the recommendation of famed orthopedic surgeon Dr. James Andrews.

PRP injections involve removing blood from the athlete, separating the plasma from the red blood cells, and injecting the plasma into the injured tissue; PRP is shorthand for platelet-rich plasma as the injected plasma is composed primarily of platelets and water. Platelets, which are small cells primarily involved with clotting, also release healing factors such as hormones.

The increased density of platelets within the injected plasma theoretically spurs the tissue to recover at an higher-rate, however, the true efficacy of PRP injections is debated.

The typical timeframe of return-to-play after Tommy John surgery is 12-18 months.

MORE FROM TWINS DAILY Latest Twins coverage from our writers Recent Twins discussion in our forums Follow Twins Daily via Twitter, Facebook or email

This story first appeared at Twins Daily and was re-shared through a collaboration with Bring Me The News.

Read the original post:
Twins Daily: How would a shortened season impact MLB injuries? - Bring Me The News

Muscular Dystrophy Association Announces Formation of Strategic Medical Advisory Team of Experts in Neuromuscular Care and Research – BioSpace

NEW YORK, April 2, 2020 /PRNewswire/ --TheMuscular Dystrophy Association(MDA) announced today the formation of its formal Medical Advisory Team who provide MDA with strategic guidance on issues that impact research and clinical care for people living with muscular dystrophy, amyotrophic lateral sclerosis (ALS) and related neuromuscular disorders more than 43 diseases. Each of the team members is a leading clinician at an MDA Care Center and is an internationally known expert in muscular dystrophy, ALS and related neuromuscular diseases. The MDA Care Center network spans over 150 locations at the nation's top medical institutions.

"We believe that engaging this team of world-class experts across neuromuscular diseases will enable MDA to lead the way in speeding the development of groundbreaking therapies and treatment paradigms that will transform the lives of those we serve," says Lynn O'Connor Vos, President and CEO of MDA. "These physicians are pillars of the neuromuscular disease community, each with focused expertise in specific diseases. Together, they will provide critical advice to MDA on our innovations in science and care programs and help ensure that we are making the maximum impact as the landscape of neuromuscular research, care and treatments evolve."

MDA's medical advisors will help lead the effort, along with more than 2,000 health care providers, to establish new clinical trials geared toward integration of MDA's innovative MOVR technology hub, which allows clinicians and researchers to share a wealth of disease-related information, establish professional protocols, and accelerate innovation.

Tonight, Dr. Barry Byrne, who will serve as chief medical advisor for the team, is joining MDA's EVP, Chief Advocacy & Care Services Officer, Kristin Stephenson for an MDA Facebook Live conversation about the precautions and best practices needed to protect the neuromuscular community in light of COVID-19. The event, scheduled for Thursday, April 2 from 6:00 to 6:30 pm EDT is accessible at https://www.facebook.com/MDAOrg/. The recording will be available for viewing after the event on MDA's COVID-19 resource page. The conversation will feature a live Q&A answering questions from people living with muscular dystrophy, ALS and related neuromuscular diseases including MDA families, and aims to provide the answers to questions regarding care duringthese uncertain times, and will cover topics related to preparedness, community impact, telemedicine and MDA's Care Center network of over 150 multidisciplinary care teams at top medical institutions nationwide.

Barry J. Byrne, MD, PhD, is an ardent supporter of newborn screening and has been an innovator and early adopter of new FDA-approved therapies that have the potential to alter the course of some neuromuscular disorders. He was the first physician to administer an approved gene therapy to a neuromuscular patient in the U.S.

"We are just beginning to realize the impact of the current revolution in the treatment of neuromuscular disorders. Newborn screening and access to newly-approved therapies are changing patients' lives when diagnosed with neuromuscular diseases; the MDA Care Center network is ready to provide these innovative treatments," says Dr. Byrne. "Disease-modifying therapies are no longer a thing of the future. There is an urgent need to bring innovative care, cutting-edge clinical research and new breakthrough treatments to the community."

Dr. Byrne will continue in his role as the associate chair of pediatrics and director of the Powell Gene Therapy Center at the University of Florida College of Medicine as he assumes this new position. He is also director of the MDA Care Center at the University of Florida.

Matthew B Harms, MD, will serve as a medical expert on ALS and other neuromuscular disorders. He is active in clinical research. Dr. Harms is associate professor of neurology at Columbia University's Vagelos College of Physicians and Surgeonsand serves at MDA's ALS Care Center at Columbia University. Dr. Harms received MDA's Diamond Award for his work directing an international effort with whole genome and transcriptome sequencing to bring precision medicine to ALS treatments.

John W. Day, MD, PhD, completes the Medical Advisory Team. Dr. Day is professor of neurology and pediatrics and director, Division of Neuromuscular Medicine at Stanford University. He directs Stanford's MDA Care Centers, which uniquely integrate the Lucile Packard Children's Hospital Pediatric and Transitional Neuromuscular Clinic with the Stanford Hospital Neuroscience Health Center's Neuromuscular and ALS Research and Clinic.The comprehensive team of investigators and clinicians in the Stanford Neuromuscular Program have helped develop novel gene modification and gene replacement treatments for spinal muscular atrophy, muscular dystrophy and ALS, and have spearheaded development of centralized data hubs like MDA's MOVR for neuromuscular disease.

About Barry J. Byrne, MD, PhD

Dr. Byrne is a clinician scientist who is studying a variety of rare diseases with the specific goal of developing therapies for inherited muscle disease. As a pediatric cardiologist, his focus is on conditions that lead to skeletal muscle weakness and abnormalities in heart and respiratory function. His group has made significant contributions to the understanding and treatment of Pompe disease, a type of neuromuscular disorder caused by an excess of a type of sugar (glycogen) in certain muscles. The research team has pioneered the use of adeno-associated virus (AAV) mediated gene therapy to restore heart and skeletal muscle function in Duchenne muscular dystrophy, Pompe, Friedrich's ataxia and other neuromuscular diseases. His group at the Powell Center has also established a series of new methods for large-scale AAV manufacturing to enable access for a wide variety of conditions.

About Matthew B. Harms, MD

Dr. Harms' post-doctoral and faculty work in neurogenetics led to the discovery of genes for dominant spinal muscular atrophy and limb-girdle muscular dystrophy type 1D. He sees patients in the Eleanor and Lou Gehrig ALS Center, the Adult Muscular Dystrophy Association Clinic, the Pediatric Muscular Dystrophy Association Clinic, and until recently, the ALS Clinic of the Bronx VA Hospital. His laboratory straddles Columbia's Motor Neuron Center and the Institute for Genomic Medicine, with a focus on generating, integrating, and analyzing clinical, genomic and transcriptomic datasets for amyotrophic lateral sclerosis and other neurological disorders.

About John W. Day, MD, PhD

Dr. Day has combined his expertise in synaptic physiology, genetics and neuromuscular medicine to help define the molecular mechanisms underlying myotonic dystrophy and other muscular dystrophies, neuropathies and ataxias. Under his leadership, the Stanford Neuromuscular Program is dedicated to the elucidation and treatment of neuromuscular diseases, integrating clinical care and clinical research with Stanford's basic science and translational programs. All Stanford pediatric and adult neuromuscular patients are asked to participate in research and are followed over time with functional evaluations. The Stanford Neuromuscular Program mission aligns fully with the goals of the MDA: to diagnose, investigate and characterize neuromuscular disorders precisely and completely; to develop novel treatments for neuromuscular disease; to incorporate novel treatments into the comprehensive care of patients with neuromuscular disorders; to advocate and support patients and families affected by neuromuscular disease so they can live life as fully and independently as possible; and to train the next generation of experts in neuromuscular diagnosis, care and research.

About MDA

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS, and related neuromuscular diseases. We do this through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research outside of the federal government, MDA has committed more than$1 billionsince our inception to accelerate the discovery of therapies and cures. Research we have supported is directly linked to life-changing therapies across multiple neuromuscular diseases. MDA's MOVR is the first and only data hub that aggregates clinical, genetic, and patient-reported data for multiple neuromuscular diseases to improve health outcomes and accelerate drug development. MDA supports the largest network of multidisciplinary clinics providing best in class care at more than 150 of the nation's top medical institutions. Our Resource Center serves the community with one-on-one specialized support, and we offer educational conferences, events, and materials for families and healthcare providers. Each year thousands of children and young adults learn vital life skills and gain independence at summer camp and through recreational programs, at no cost to families. For more information visitmda.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/muscular-dystrophy-association-announces-formation-of-strategic-medical-advisory-team-of-experts-in-neuromuscular-care-and-research-301033945.html

SOURCE Muscular Dystrophy Association

Read the original post:
Muscular Dystrophy Association Announces Formation of Strategic Medical Advisory Team of Experts in Neuromuscular Care and Research - BioSpace

Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients – The New York Times

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response. He said one risk with the natural killer cells is they could go in the other direction, exacerbating respiratory problems by massive killing of the patients respiratory cells.

Despite the scant evidence, Mr. Giuliani has become an early booster, interviewing Dr. Hariri on a podcast published on his website Saturday, and praising the treatment on Twitter, saying, this therapy has real potential. In a tweet on Saturday, he added, Lets hope F.D.A. can recognize that their cumbersome process designed to keep us safer, if it is not altered dramatically in times of great need, can result in unimaginable loss of human life.

Around the same time, Twitter deleted a post by Mr. Giuliani that it said violated its rules. The tweet, from March 27, made unfounded claims about the malaria drug hydroxychloroquine, one of the treatments that Mr. Trump has supported.

Dr. Hariri said that he has known Mr. Giuliani for years and that the appearance on his podcast was a friendly chat between people who know each other and who share a common interest in this particular response to this disease.

He said that he has no business relationship with Mr. Giuliani, and that Mr. Giuliani is not representing him in any way, either paid or unpaid. I dont have anything to do with what the mayor tweets or whatnot, and I dont agree or disagree with anything, he said.

Dr. Hariri said the company would follow the established process for testing whether a drug works. We have waited for the F.D.A. to complete their review, which they did in a heroic and quick fashion, he said.

On Wednesday evening the same day the F.D.A. approved his trial Dr. Hariri praised the appearance by the agencys commissioner, Dr. Stephen Hahn, on the conservative Fox News talk show The Ingraham Angle.

We are fortunate to have Dr. Hahn at the helm, he tweeted.

Link:
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients - The New York Times

Stem Cell Therapy for Colon Cancer – Yahoo Finance

WASHINGTON, April 2, 2020 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 245, Issue 6, March 2020) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220910690) examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, co-author on the study, said that "Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: "Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit http://www.sebm.org. For anyone interested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

logo.png Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/stem-cell-therapy-for-colon-cancer-301033659.html

SOURCE Experimental Biology and Medicine

See the original post here:
Stem Cell Therapy for Colon Cancer - Yahoo Finance

Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa – BioSpace

HAMBURG, Germany and TORONTO, April 2, 2020 /CNW/ - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the innovative biotechnology company panCELLa Inc. announced today that the companies have entered into a licensing and investment agreement.

Under the terms of the agreement, Evotec will receive a non-exclusive licence to access panCELLa's proprietary iPS cell lines "iACT Stealth Cells", which are genetically modified to prevent immune rejection of derived cell therapy products ("cloaking"). Furthermore, Evotec will also have access to a new-generation cloaking technology known as hypoimmunogenic cells. In addition, the "FailSafe" mechanism effectively addresses a key challenge in iPSC-based cell therapy, potential tumour formation by residual undifferentiated cells.

Using the cell lines, Evotec will be able to develop iPSC-based, off-the-shelf cell therapies with long-lasting efficacy that can be safely administered to a broad population of patients without the use of medication to supress the patients' immune system. With a growing portfolio of iPSC-based cell therapy projects at Evotec, access to research as well as GMP-grade iPSC lines modified with one or both of the panCELLa technologies significantly accelerates Evotec's cell therapy discovery and development efforts. Modified iPSC lines will be available for the development of cell therapy approaches across a broad range of indications by Evotec and potential partners. Furthermore, Evotec has made an investment to take a minority stake in panCELLa and has nominated Dr Andreas Scheel to join panCELLa's supervisory board.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Cell therapies hold enormous potential as truly regenerative or curative approaches for a broad range of different diseases with significant medical need. Integrating panCELLa's technology and cell lines into our ongoing proprietary research and development efforts strengthens Evotec's position in cell therapy. It is our goal to provide safe highly-effective cell therapy products to as many patients as possible. In addition to small molecules and biologics, cell therapy will become yet another major pillar of Evotec's multimodality discovery and development platform."

Mahendra Rao, MD, PhD, CEO at panCELLa, added: "We welcome the partnership with Evotec. Evotec's widely recognised expertise and existing portfolio of iPSC-related technology platforms will allow panCELLa to rapidly advance its own therapeutic interests in NK cell therapy, pancreatic islet production and iPSC-derived MSC platform, in addition to enabling panCELLa to make its platform technologies widely available. I believe that the investment by Evotec in our company is a strong validation of the leading role of panCELLa in the field of regenerative medicine and in the utility of its platform technologies. We welcome Dr Andreas Scheel to our Board."

No financial details of the agreement were disclosed.

About Evotec and iPSCInduced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka's lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. He was awarded the 2012 Nobel Prize along with Sir John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent". Pluripotent stem cells hold great promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.

Evotec has built an industrialised iPSC infrastructure that represents one of the largest and most sophisticated iPSC platforms in the industry. Evotec's iPSC platform has been developed over the last years with the goal to industrialise iPSC-based drug screening in terms of throughput, reproducibility and robustness to reach the highest industrial standards, and to use iPSC-based cells in cell therapy approaches via the Company's proprietary EVOcells platform.

About cell therapy and panCELLa's FailSafe iPSC technologyCell therapy, one of the most promising regenerative medicine approaches, replaces a patient's missing or broken cells with functioning cells from a range of different sources, either from a donor, from the patient's own material, or from stem cells. The advent of induced pluripotent stem cells ("iPSC") has opened up stem cells as an almost unlimited source of consistent-quality material for such cell therapies. At the same time, differentiating cell therapies from a single validated source circumvents critical risks of contamination associated with administering both donor and patient cell material.

However, the patient's immune system will treat such iPSC-based transplant as "foreign" and use the body's immune system to counteract the therapy, thus undermining its long-term efficacy. While organ transplants require an often lifelong regimen of immunosuppressants, iPSC-derived cells used for cell therapies can be cloaked to make them undetectable by the patient's immune system, thus avoiding rejection and enabling effective long-term relief of the patient's symptoms.

To increase the safety of such iPSC-derived cell products, panCELLa's proprietary FailSafe technology is able to inactivate any iPSC-derived proliferating cell before and after transplantation through the use of a readily available anti-infective medication. FailSafe is the only quantifiable "safety switch" on the market which is expected to be critical for regulators, clinicians and patients to make informed decisions when evaluating treatment options.

About panCELLa Inc. Incorporated in August 2015, panCELLa (www.pancella.com) was founded by Dr Andras Nagy and Dr Armand Keating based on Dr Nagy's ground-breaking work in the area of stem cell research. Through panCELLa, Drs Keating and Nagy are seeking to create an effective cell therapy derived from stem cells, which are modified to provide a sufficient and very high level of safety before and after the cells are introduced to the patient. panCELLa serves those companies developing products from stem cells. panCELLa seeks to create universal "off the shelf" FailSafe Cells and to assist pharmaceutical and biotechnology sectors to achieve such with their own cell lines. Targeted medical applications include deadly, debilitating, or aggressive diseases requiring immediate treatment where there is no time to cultivate a customized stem cell treatment from the patient (i.e. cancer, cardiac infarct, diabetes, stroke and spinal cord injury).

About Evotec SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,000 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

FORWARD LOOKING STATEMENTSInformation set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

SOURCE panCELLa Inc.

Company Codes: Frankfurt:EVT, OTC-PINK:EVTCY

More:
Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa - BioSpace

Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia – Yahoo Finance

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Results of the study, conducted by researchers in China, have been published in Aging and Disease.1

We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis.

The study, which evaluated clinical outcomes as well as changes in inflammatory and immune function for 14 days in seven patients with COVID-19 pneumonia, indicated that intravenous transplantation of MSCs was a safe and effective treatment for patients with COVID-19 pneumonia, including for those in severe condition.

Pulmonary function and symptoms of these seven patients were significantly improved within two days of MSC transplantation. Three of the patients, including one classified as severe, recovered and were discharged 10 days after treatment.

CyTOF analysis found that MSC treatment of severe cases led to disappearance in three to six days of overactivated cytokine-secreting immune cells and increases in regulatory T and dendritic cells. Importantly, there was a dramatic increase in a population of CD14+CD11c+CD11bmidregulatory dendritic cells, which may have helped to tamp down the cytokine storm associated with COVID-19 respiratory disease. Separate analysis of patient serum found significant reduction in levels of TNF-, a potent inflammatory cytokine, while IL-10, an anti-inflammatory cytokine, increased in the MSC treatment group compared to the placebo control group.

Story continues

This level of new and valuable treatment research based on broad-based immune profiling is an important front in the COVID-19 fight, said Chris Linthwaite, President and CEO of Fluidigm. Fluidigm is actively engaged with many researchers in government and medical institutions who are addressing the COVID-19 pandemic from the perspectives of both immune profiling and virus detection and testing, and this study underscores the critical role that our technologies are playing in the global response to the outbreak.

In addition to our instruments, our assays and analysis software are increasingly the focus of customers in the global research community exploring immune profiling of COVID-19 infected populations. Our Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter analysis software are a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers, Linthwaite said.

We are inspired by this opportunity to provide meaningful tools in efforts to develop innovative solutions to this rapidly evolving pandemic.

About FluidigmFluidigm(FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

1 Leng, Z., Zhu, R., Hou, W. et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease 11 (2020): 216228.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

View post:
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia - Yahoo Finance